Celldex Therapeutics Appoints Industry Veteran Teri Lawver As Senior Vice President And Chief Commercial Officer, Succeeding Richard Wright Upon His Retirement After 10 Years

Celldex Therapeutics, Inc., has announced the appointment of Teri Lawver as Senior Vice President and Chief Commercial Officer. Ms. Lawver, a seasoned global healthcare leader with three decades of experience, succeeds Richard Wright, who will retire after more than ten years of dedicated service and leadership at Celldex.

With over 30 years of strategic, commercial launch, and operational leadership across the biopharmaceutical, medical device, and consumer health technology sectors, Ms. Lawver brings a wealth of experience to Celldex as the company prepares for the potential commercialization of its lead program, barzolvolimab, and continues to expand its pipeline in immunology and inflammation.

Anthony Marucci, Co-founder, President, and Chief Executive Officer of Celldex, welcomed Ms. Lawver to the leadership team, stating, “We are thrilled to have Teri join Celldex at this important time in our growth. She brings an extraordinary track record of success across global biopharmaceutical and medical technology organizations. Her deep expertise in immunology and inflammation, coupled with her proven ability to build and scale commercial operations, will be invaluable as we advance barzolvolimab and our broader pipeline. I would also like to express my sincere gratitude to Rick Wright for his decade of exceptional leadership and commitment. His contributions have been instrumental in shaping Celldex’s progress and positioning us for our next phase of growth. We wish him the very best in his well-deserved retirement.”

Ms. Lawver’s extensive background spans multiple therapeutic areas and major product launches. During her career, she has led and supported the advancement and commercialization of several groundbreaking treatments in immunology and inflammation, including pivotal indications for REMICADE® (infliximab), STELARA® (ustekinumab), and TREMFYA® (guselkumab). Prior to joining Celldex, she was Principal and Owner of Thera Lifescience Advisors, providing strategic guidance to CEOs and investors in innovative life science and health technology companies.

Before founding Thera Lifescience Advisors, Ms. Lawver served as Chief Commercial Officer at Dexcom, Inc., where she oversaw $4 billion in annual revenue and managed a global team of 1,900 employees across 50 countries. She previously spent 20 years at Johnson & Johnson, where she held several senior leadership roles across diverse business units worldwide, culminating in her position as Worldwide Vice President for Janssen Immunology. At J&J, she played a pivotal role in advancing biologic therapies and had earlier contributed to the launch of the industry’s first biologics in the gastroenterology field while working with Centocor, a J&J subsidiary.

Earlier in her career, Ms. Lawver was an Associate Principal at McKinsey & Company, where she was a leader in the firm’s Healthcare Practice, and she began her professional journey as a Derivatives Analyst at Bloomberg Financial Markets. She currently serves on the Board of Directors of Altimmune, Inc. Ms. Lawver holds a Bachelor of Science degree in Linguistics from Georgetown University and an MBA from Duke University’s Fuqua School of Business.

Speaking about her new role, Ms. Lawver said, “I am delighted to join Celldex at such a transformative time in the company’s journey. Celldex’s pioneering work in mast cell biology and its dedication to improving outcomes for patients with severe allergic and inflammatory diseases are truly inspiring. I look forward to working alongside the talented Celldex team to help bring these promising therapies to patients who need them most.”